DR. ANSON WARREN LOWE, M.D.
Osteopathic Medicine in Palo Alto, CA
License number
California G54277
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
300 Pasteur Dr Alway Building, Palo Alto, CA 94305
Phone
(650) 725-6764
(650) 723-5488 (Fax)
(650) 723-5488 (Fax)
Professional information
Dr. Anson W Lowe, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
STANFORD MEDICAL GROUP
900 Blake Wilbur Dr, Palo Alto 94304
(650) 725-8409 (Phone), (650) 725-7078 (Fax)
STANFORD UNIV MEDICAL CENTER
300 Pasteur Dr STE M211, Stanford 94305
(650) 736-5555 (Phone), (650) 725-9113 (Fax)
900 Blake Wilbur Dr, Palo Alto 94304
(650) 725-8409 (Phone), (650) 725-7078 (Fax)
STANFORD UNIV MEDICAL CENTER
300 Pasteur Dr STE M211, Stanford 94305
(650) 736-5555 (Phone), (650) 725-9113 (Fax)
Certifications:
Gastroenterology, 1987, Internal Medicine, 1983
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
STANFORD MEDICAL GROUP
900 Blake Wilbur Dr, Palo Alto 94304
STANFORD UNIV MEDICAL CENTER
300 Pasteur Dr STE M211, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
900 Blake Wilbur Dr, Palo Alto 94304
STANFORD UNIV MEDICAL CENTER
300 Pasteur Dr STE M211, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Mount Sinai School of Medicine
Graduated: 1980
Presby-Colum Med Ctr
U Calif
Mount Sinai School of Medicine
Graduated: 1980
Presby-Colum Med Ctr
U Calif
Anson Warren Lowe, Stanford CA
Specialties:
Gastroenterologist
Address:
300 Pasteur Dr, Stanford, CA 94305
Education:
Mount Sinai School of Medicine - Doctor of Medicine
UCSF Medical Center - Fellowship - Gastroenterology (Internal Medicine)
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Internal Medicine
UCSF Medical Center - Fellowship - Gastroenterology (Internal Medicine)
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)
Methods And Compositions For Detecting Pancreatic Disease
US Patent:
2012010, May 3, 2012
Filed:
Nov 4, 2011
Appl. No.:
13/289658
Inventors:
Anson Lowe - Stanford CA, US
International Classification:
A61K 38/43, G01N 33/566, A61P 1/18, G01N 33/53
US Classification:
424 941, 435 71, 436501
Abstract:
Methods and compositions for at least determining whether a human subject has a pancreatic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a pancreatic glycoprotein (GP2) analyte to determine whether the subject at least has the pancreatic disease. Also provided are kits, systems, and devices for practicing the subject methods.
Methods And Compositions For Detecting Pancreatic Disease
US Patent:
2007027, Nov 29, 2007
Filed:
Jul 26, 2004
Appl. No.:
11/632260
Inventors:
Anson Lowe - Stanford CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. U - Palo Alto CA
International Classification:
G01N 33/574
US Classification:
435007230, 436501000
Abstract:
Methods and compositions for at least determining whether a human subject has a pancreatic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a pancreatic glycoprotein (GP2) analyte to determine whether the subject at least has the pancreatic disease. Also provided are kits, systems, and devices for practicing the subject methods.
Use Of Agr3 For Treating Cancer
US Patent:
2014005, Feb 20, 2014
Filed:
Feb 27, 2012
Appl. No.:
14/000182
Inventors:
Anson W. Lowe - Stanford CA, US
Aiwen Dong - Stanford CA, US
Aiwen Dong - Stanford CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - PALO ALTO CA
International Classification:
A61K 38/17, A61K 45/06
US Classification:
424450, 514 193, 424490, 514 44 R
Abstract:
Embodiments are related to processes for using an Anterior Gradient Homolog 3 (AGR3) therapeutic to treat an enhanced AGR2 expressing cancer, or its premalignant precursor, comprising administering an amount of an AGR3 therapeutic to a human patient in need thereof.